Biotech entity
Every one of those 3 sits in a single category, pharma. They are less corroborated than the beat average, carrying 2.3 original sources each against 3.7 for the same window. Aparna Thakur is the most frequent co-covered peer, appearing in 1 of the 3 tracked stories.
Last mentioned: Jul 27, 2026
Entity pulse
Coverage balance Balanced directional read. Positive and negative coverage are within 0 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 3 sits in a single category, pharma. They are less corroborated than the beat average, carrying 2.3 original sources each against 3.7 for the same window. Aparna Thakur is the most frequent co-covered peer, appearing in 1 of the 3 tracked stories. The 159-day window averages about 0.1 stories each week. At 6, the average consequence score sits below the same-window beat average of 6.2. We currently track 3 Biotech stories that mention Evotec, published between February 19, 2026 and July 27, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 613 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Evotec. Shared-story counts are live from our verified record — not editorial picks.
CBO Appointment
Christiane Bardroff is officially named Chief Business Officer to lead global commercial strategy.
Denmark Expansion
Company announces further $1.2 billion investment to double capacity at its Hillerød site.
Holly Springs Investment
Fujifilm announces $2 billion investment in a new large-scale cell culture facility in North Carolina.
A new DelveInsight forecast projects a 47% CAGR for the Alport syndrome market through 2036, fueled by a pipeline of gene and targeted therapies. The report highlights ELX-02 from Eloxx as a potential first-mover gene therapy with an 8-week dosing interval, while big pharma players like Bayer and Novartis advance competitors.
Source: prnewswire.com · finanznachrichten.de
FUJIFILM Biotechnologies has appointed industry veteran Christiane Bardroff as Chief Business Officer to lead its global commercial strategy. The move comes as the company nears the completion of multi-billion dollar manufacturing expansions in the United States and Europe.
Halozyme Therapeutics reported a strong revenue beat of $451 million for the fourth quarter, driven by its ENHANZE platform royalties, yet surprised investors with a significant non-GAAP EPS miss of $2.44. The discrepancy suggests substantial one-time charges or strategic shifts that contrast with the company's robust top-line growth.
Source: Seeking Alpha · Seeking Alpha
Evotec is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
